PD-1 AND PD-L1 INHIBITOR MARKET ANALYSIS

The unsustainably high cost of cancer treatment is a major restraint on the growth of the PD-1 and PD-L1 inhibitor market. Cancer treatments have become exorbitantly expensive over the past few decades, to the point where they cause financial distress for many patients and their families . Healthcare systems and insurance companies around the world struggle with providing coverage and reimbursement for such expensive therapies. Many are unable to bear the brunt of the costs, leaving patients in the lurch.

Market Opportunities: Rise in the research and development activities

Rise in research and development activities are expected to offer significant growth opportunities for players in the PD-1 and PD-L1 inhibitor market. For instance, market players are increasingly investing in research and development activities to meet the increasing demand. Researchers at Johns Hopkins Kimmel Cancer Center are leading the way in developing novel immunotherapies called anti-PD-1 and anti-PD-L1 for people with advanced melanomas. The aim of the therapy is not to kill cancer cells directly, but to block a pathway that protects tumor cells from components of the immune system that are capable and ready to fight cancer.